Nanotherapy for posterior eye diseases

被引:135
作者
Kaur, Indu Pal [1 ]
Kakkar, Shilpa [1 ]
机构
[1] Panjab Univ, UGC, Ctr Adv Study, Univ Inst Pharmaceut Sci, Chandigarh 160014, India
关键词
Controlled release; Liposomes; Delivery to the vitreous; Topical delivery; Nanoparticles; Retina; OCULAR DRUG-DELIVERY; PIGMENT EPITHELIAL-CELLS; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; LIPOSOME-ENCAPSULATED GANCICLOVIR; NANOSTRUCTURED LIPID CARRIERS; INTRAVITREAL INJECTION; RABBIT MODEL; RETINAL TOXICITY; GENE DELIVERY; IN-VIVO;
D O I
10.1016/j.jconrel.2014.05.031
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
It is assumed that more than 50% of the most enfeebling ocular diseases have their origin in the posterior segment. Furthermore, most of these diseases lead to partial or complete blindness, if left untreated. After cancer, blindness is the second most dreaded disease world over. However, treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted for delivery to this segment. In this regard, nanostructured drug delivery systems are proposed to defy ocular barriers, target retina, and act as permeation enhancers in addition to providing a controlled release. Since an important step towards developing effective treatment strategies is to understand the course or a route a drug molecule needs to follow to reach the target site, the first part of the present review discusses various pathways available for effective delivery to and clearance from the posterior eye. Promise held by nanocarrier systems, viz. liposomes, nanoparticles, and nanoemulsion, for effective delivery and selective targeting is also discussed with illustrative examples, tables, and flowcharts. However, the applicability of these nanocarrier systems as self-administration ocular drops is still an unrealized dream which is in itself a huge technological challenge. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:100 / 112
页数:13
相关论文
共 151 条
[1]   PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION [J].
Abrishami, Majid ;
Ganavati, Siamak Zarei ;
Soroush, Dina ;
Rouhbakhsh, Majid ;
Jaafari, Mahmoud R. ;
Malaekeh-Nikouei, Bizhan .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (05) :699-703
[2]   Amphiphilic block copolymers for drug delivery [J].
Adams, ML ;
Lavasanifar, A ;
Kwon, GS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (07) :1343-1355
[3]  
AHMED I, 1985, INVEST OPHTH VIS SCI, V26, P584
[4]   TREATMENT OF CYTOMEGALOVIRUS RETINITIS WITH INTRAVITREAL INJECTION OF LIPOSOME-ENCAPSULATED GANCICLOVIR IN A PATIENT WITH AIDS [J].
AKULA, SK ;
MA, PE ;
PEYMAN, GA ;
RAHIMY, MH ;
HYSLOP, NE ;
JANNEY, A ;
ASHTON, P .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1994, 78 (09) :677-680
[5]   LIPOSOME-BOUND CYCLOSPORINE - RETINAL TOXICITY AFTER INTRAVITREAL INJECTION [J].
ALGHADYAN, AA ;
PEYMAN, GA ;
KHOOBEHI, B ;
LIU, KR .
INTERNATIONAL OPHTHALMOLOGY, 1988, 12 (02) :105-107
[6]  
Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
[7]   Transscleral drug delivery to the retina and choroid [J].
Ambati, J ;
Adamis, AP .
PROGRESS IN RETINAL AND EYE RESEARCH, 2002, 21 (02) :145-151
[8]   Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride [J].
Ammar, Hussein O. ;
Salama, H. A. ;
Ghorab, M. ;
Mahmoud, A. A. .
AAPS PHARMSCITECH, 2009, 10 (03) :808-819
[9]  
Amrite AC, 2008, MOL VIS, V14, P150
[10]  
[Anonymous], 2013, J. Clin. Exp. Ophthalmol